the new patented compounds are based on a potent reversible noncovalent mechanism of action, which is useful for treating MAGL-mediated diseases, such as neuroinflammation/degeneration, pain, multiple sclerosis/amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease.
Research Institution:
Università di Pisa
